Can we improve ABVD in Hodgkin's lymphoma?
Mené sur 51 patients atteints d'un lymphome hodgkinien de stade avancé, cet essai de phase I évalue la dose maximale tolérée et l'efficacité du brentuximab vedotin, en combinaison avec une chimiothérapie ABVD ou AVD, pour un traitement de première ligne
Brentuximab vedotin is an antibody—drug conjugate—the antibody targets CD30 and is linked to the microtubule-disrupting agent auristatin. Although the unconjugated antibody had little, if any, activity in Hodgkin's lymphoma, when the conjugate was given as a single agent to patients with relapsed or refractory Hodgkin's lymphoma, 76 (75%, 95% CI 64·9—82·6) of 102 patients achieved an objective response, and 35 (34%, 95% CI 25·2—44·4) patients had complete remission...